-
Fierce Biotech3 months ago
Chutes & Ladders—Tang takes over Aurinia after FDA brouhaha
Seasoned biotech takeover titan Kevin Tang has struck again. After serving as board chair of Aurinia since 2024, Tang has now ascended to the CEO spot...
-
Endpoints News3 months ago
UCB picks Georgia for $2B biologics site; AbbVie exec visits China
UCB has selected Gwinnett County, GA, as the location for its new biologics factory. The 460,000-square-foot facility is expected to cost $2 billion and will supply...
-
Endpoints News3 months ago
New tech, familiar problems
I’ve been on the hunt for a referral to see a new physical therapist. So I decided to try out Doctronic, which markets itself as an...
-
BioPharma Dive – AI / Data3 months agoMerck’s deal for Terns sparks debate over a possible biotech bidding war
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming.
-
AI & Machine Learning in Biotechnology3 months agoSTAT+: Denali Therapeutics, Corcept Therapeutics win FDA approvals
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The FDA granted accelerated approval...
-
AI & Machine Learning in Biotechnology3 months agoHealth influencers talk social media and mental health
A jury in Los Angeles has found social media giants Google and Meta liable for the mental health struggles of a 20-year-old woman, awarding her $3...
-
BioPharma Dive – AI / Data3 months agoFDA clears Denali drug in ‘clear step’ for rare disease biotechs
The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance...
-
Biotech Industry Intelligence3 months ago
Wave crashes on obesity disappointment
Wave crashes on obesity disappointment
-
AI & Machine Learning in Biotechnology3 months agoSTAT+: A surprise opening for health care reforms
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your...
-
BioPharma Dive – AI / Data3 months agoWave crashes on obesity drug update; Kodiak’s reboot pays dividends
Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
